(Q33736193)

29 July 2017

0 references

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study (English)

1 reference

29 July 2017

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Simona Malucchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Marco Capobianco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Marianna Lo Re

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Maria Malentacchi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Alessia di Sapio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Manuela Matta

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Francesca Sperli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

3 December 2016

1 reference

27915429

29 July 2017

published in

Neurology and therapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

145-152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40120-016-0058-0

6 June 2020

exact match

0 references

cites work

Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Optimizing treatment success in multiple sclerosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447551

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

14 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40120-016-0058-0

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27915429

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27915429

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27915429

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40120-016-0058-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

6 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27915429%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

27915429

1 reference